SEC Tracker
Get the app

Xenon Pharmaceuticals XENE

Xenon Pharmaceuticals reported Q3 2026 results

Xenon Pharmaceuticals (XENE) filed an 8-K with the SEC on Nov 9, 2026, 4:00 pm ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results, Item 7.01 Investor disclosure

Form
8-K
Filed
Importance
Major
  1. New Drug Application for azetukalner in focal seizures submitted to FDA in September 2026
  2. Cash, cash equivalents, and marketable securities of $1.2 billion with cash runway into 2029
  3. Topline data from Phase 3 X-NOVA2 study in MDD expected in December 2026
  4. Positive Phase 1 data for XEN1701 and XEN1120 pain programs presented at IASP World Congress

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Xenon Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.